Literature DB >> 24363390

Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.

Onno W Akkerman1, Richard van Altena, Mathieu S Bolhuis, Tjip S van der Werf, Jan-Willem Alffenaar.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24363390      PMCID： PMC3910774          DOI： 10.1128/AAC.01535-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs.

Authors:  Jan-Willem C Alffenaar
Journal:  J Infect Dis       Date:  2012-03-29       Impact factor: 5.226

Review 2.  Dried blood spots: a new tool for tuberculosis treatment optimization.

Authors:  D H Vu; J W C Alffenaar; P M Edelbroek; J R B J Brouwers; D R A Uges
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.

Authors:  A D Pranger; R van Altena; R E Aarnoutse; D van Soolingen; D R A Uges; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Eur Respir J       Date:  2011-02-10       Impact factor: 16.671

Review 5.  Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

Authors:  W Fox; G A Ellard; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  1999-10       Impact factor: 2.373

6.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Authors:  Erlina Burhan; Carolien Ruesen; Rovina Ruslami; Arum Ginanjar; Hadiarto Mangunnegoro; Purwantyastuti Ascobat; Rogier Donders; Reinout van Crevel; Rob Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

8.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
  8 in total
  2 in total

1.  Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.

Authors:  Abdullah Alsultan; Guohua An; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Authors:  Jong Sun Park; Jae-Yeon Lee; Yeon Joo Lee; Se Joong Kim; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Junghan Song; Jae Ho Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.